{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'Enrollment criteria vary across active surveillance cohorts, but in general enrollment', 'is offered only to those with favorable risk prostate cancer, which can be defined as', 'very low-risk to low-intermediate risk disease (i.e., low-volume Gleason 3+4', 'disease) 40,41,48 In general, local intervention is recommended upon pathologic', 'reclassification (i.e., increased tumor volume or Gleason score), with some also', 'recommending intervention following a change in PSA kinetics. 13,14,46 The reported', 'reasons men leave active surveillance in pursuit of treatment include: Gleason grade', 'change (8% to 38%), PSA increase (14% to 26%) and anxiety (3% to 9%). 49', 'As conducted at Johns Hopkins, active surveillance focuses on men with very low-', 'risk disease as defined per the Epstein criteria (i.e., T1c stage, PSA density <0.15', 'ng/mL, PSA <10 ng/mL, Gleason <6, 2 cores involved and <50% cancer in any given', 'core)', '11,13,41 Approximately 80% of men enrolled in the active surveillance program at', 'Johns Hopkins met all criteria for very low-risk disease, with the other 20% failing to', 'meet the PSA <10 ng/mL requirement only. Surveillance has entailed semiannual PSA', 'measurements with digital rectal exam (DRE) and an annual 12 to 14 core biopsy.', 'Curative local therapy is in turn only recommended upon pathologic upgrade from the', 'enrollment criteria. To date, 1,134 men have enrolled in active surveillance, with 508', '(45%) men exiting the program. Out of those who have exited, 298 (26%) were', 'secondary to pathologic upstaging, 99 (9%) elected to undergo treatment in spite of', 'stable pathology and 113 (10%) electively withdrew from the program (Figure 2). Out of', 'the 113 that electively withdrew from active surveillance, 66 (58.4%) were lost to follow-', 'up. in regard to those who exited active surveillance due to pathologic upstaging, 130', '(44%) exited due to Gleason score upgrading, 168 (56%) exited due to an increase in', 'disease volume (i.e. total number of effected cores >2 or >50% involvement in any', 'given core). Within two years 143 (12.6%) exited; 65 (45%) due to Gleason score', 'upgrading and 78 (55%) due to an increase in disease volume. Only one of the', 'subjects on active surveillance at Johns Hopkins has died as a result of prostate cancer', 'Unpublished data). 13', '17', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'Tx', 'LOZO', 'Exits (508)', '298 pathologic, Tx at JHMI', '99 elective, Tx at JHMI', 'Very low risk', '113 Withdrawals', 'Prostate Cancer', 'AS', '(737)', '45 deaths', 'other causes,', '1 PCa death', 'Figure 2: Johns Hopkins active surveillance schematic. AS, active surveillance; Tx,', 'local treatment (e.g. prostatectomy, radiation therapy); JHMI, Johns Hopkins', 'Medical Institution; PCa, prostate cancer.', 'In contrast to the Johns Hopkins active surveillance cohort, the University of', 'Toronto cohort allows select patients with intermediate-risk prostate cancer to enroll. 14', 'Prior to the year 2000, patients >70 years-old who had a PSA up to 15 ng/ml or a', 'Gleason score <3+4 were allowed to enroll. After 2000, any patient could enroll if they', 'had a PSA of 10-20 ng/ml and/or a Gleason score <3+4 as long as they had a life', 'expectancy of <10 years and significant comorbidities. Gleason 7 patients with primary', 'pattern 4 disease were excluded given that these patients have been shown to have', 'poorer outcomes compared to primary pattern 3 patients. 48 Out of 993 men enrolled', \"onto this cohort, 25% fulfilled the D'Amico criteria for intermediate risk. 40 After a median\", 'follow up of 6.4 years, 27% of men have received intervention for their prostate cancer.', 'Reasons for leaving the program include: short PSA doubling time (11.7%), grade', '18', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}